REPORT ID 2847

China Angiogenesis Modulators Market Research Report 2017

Publish Date
11-Dec-17
Pages
112
Format
Electronic (PDF)

The global Angiogenesis Modulators market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Angiogenesis Modulators development status and future trend in China, focuses on top players in China, also splits Angiogenesis Modulators by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
    Celgene Corporation (USA)
    Eisai Co., Ltd. (Japan)
    Amgen, Inc. (USA)
    Genentech, Inc. (USA)
    GlaxoSmithKline plc (UK)
    Bayer Pharma AG (Germany)
    Bionomics Ltd. (Australia)
    CASI Pharmaceuticals, Inc. (USA)
    AstraZeneca plc (UK)
    Eli Lilly and Company (USA)
    F.Hoffmann-La Roche AG (Switzerland)

Geographically, this report splits the China market into six regions,
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into
    Angiogenesis Inhibitors
    Angiogenesis Stimulators
    Angiogenin
    Others

On the basis of the end users/application, this report covers
    Breast Cancer
    Colorectal Cancer
    Lung Cancer
    Prostate Cancer
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

China Angiogenesis Modulators Market Research Report 2017
1 Angiogenesis Modulators Overview
    1.1 Product Overview and Scope of Angiogenesis Modulators
    1.2 Classification of Angiogenesis Modulators by Product Category
        1.2.1 China Angiogenesis Modulators Sales (K MT) Comparison by Type (2012-2022)
        1.2.2 China Angiogenesis Modulators Sales (K MT) Market Share by Type in 2016
        1.2.3 Angiogenesis Inhibitors
        1.2.4 Angiogenesis Stimulators
        1.2.5 Angiogenin
        1.2.6 Others
    1.3 China Angiogenesis Modulators Market by Application/End Users
        1.3.1 China Angiogenesis Modulators Sales (K MT) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Breast Cancer
        1.3.3 Colorectal Cancer
        1.3.4 Lung Cancer
        1.3.5 Prostate Cancer
        1.3.6 Others
    1.4 China Angiogenesis Modulators Market by Region
        1.4.1 China Angiogenesis Modulators Market Size (Million USD) Comparison by Region (2012-2022)
        1.4.2 South China Angiogenesis Modulators Status and Prospect (2012-2022)
        1.4.3 East China Angiogenesis Modulators Status and Prospect (2012-2022)
        1.4.4 Southwest China Angiogenesis Modulators Status and Prospect (2012-2022)
        1.4.5 Northeast China Angiogenesis Modulators Status and Prospect (2012-2022)
        1.4.6 North China Angiogenesis Modulators Status and Prospect (2012-2022)
        1.4.7 Central China Angiogenesis Modulators Status and Prospect (2012-2022)
    1.5 China Market Size (Sales and Revenue) of Angiogenesis Modulators (2012-2022)
        1.5.1 China Angiogenesis Modulators Sales (K MT) and Growth Rate (%)(2012-2022)
        1.5.2 China Angiogenesis Modulators Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 China Angiogenesis Modulators Market Competition by Players/Manufacturers
    2.1 China Angiogenesis Modulators Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2 China Angiogenesis Modulators Revenue and Share by Players/Manufacturers (2012-2017)
    2.3 China Angiogenesis Modulators Average Price (USD/MT) by Players/Manufacturers (2012-2017)
    2.4 China Angiogenesis Modulators Market Competitive Situation and Trends
        2.4.1 China Angiogenesis Modulators Market Concentration Rate
        2.4.2 China Angiogenesis Modulators Market Share of Top 3 and Top 5 Players/Manufacturers
        2.4.3 Mergers & Acquisitions, Expansion in China Market
    2.5 China Players/Manufacturers Angiogenesis Modulators Manufacturing Base Distribution, Sales Area, Product Types

3 China Angiogenesis Modulators Sales and Revenue by Region (2012-2017)
    3.1 China Angiogenesis Modulators Sales (K MT) and Market Share by Region (2012-2017)
    3.2 China Angiogenesis Modulators Revenue (Million USD) and Market Share by Region (2012-2017)
    3.3 China Angiogenesis Modulators Price (USD/MT) by Regions (2012-2017)

4 China "&B1&" Sales and Revenue by Type/ Product Category (2012-2017)"
    4.1 China Angiogenesis Modulators Sales (K MT) and Market Share by Type/ Product Category (2012-2017)
    4.2 China Angiogenesis Modulators Revenue (Million USD) and Market Share by Type (2012-2017)
    4.3 China Angiogenesis Modulators Price (USD/MT) by Type (2012-2017)
    4.4 China Angiogenesis Modulators Sales Growth Rate (%) by Type (2012-2017)

5 China "&B1&" Sales by Application (2012-2017)"
    5.1 China Angiogenesis Modulators Sales (K MT) and Market Share by Application (2012-2017)
    5.2 China Angiogenesis Modulators Sales Growth Rate (%) by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6 China Angiogenesis Modulators Players/Suppliers Profiles and Sales Data
    6.1 Celgene Corporation (USA)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Angiogenesis Modulators Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Celgene Corporation (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Eisai Co., Ltd. (Japan)
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Angiogenesis Modulators Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Eisai Co., Ltd. (Japan) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Amgen, Inc. (USA)
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Angiogenesis Modulators Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Genentech, Inc. (USA)
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Angiogenesis Modulators Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 GlaxoSmithKline plc (UK)
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Angiogenesis Modulators Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bayer Pharma AG (Germany)
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Angiogenesis Modulators Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Bionomics Ltd. (Australia)
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Angiogenesis Modulators Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 CASI Pharmaceuticals, Inc. (USA)
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Angiogenesis Modulators Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 AstraZeneca plc (UK)
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Angiogenesis Modulators Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Eli Lilly and Company (USA)
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Angiogenesis Modulators Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (%)(2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 F.Hoffmann-La Roche AG (Switzerland)

7 Angiogenesis Modulators Manufacturing Cost Analysis
    7.1 Angiogenesis Modulators Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Angiogenesis Modulators

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Angiogenesis Modulators Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Angiogenesis Modulators Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 China Angiogenesis Modulators Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 China Angiogenesis Modulators Sales (K MT), Revenue (Million USD) Forecast (2017-2022)
    11.2 China Angiogenesis Modulators Sales (K MT) Forecast by Type (2017-2022)
    11.3 China Angiogenesis Modulators Sales (K MT) Forecast by Application (2017-2022)
    11.4 China Angiogenesis Modulators Sales (K MT) Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List